Martin Kornacker

1.9k total citations
59 papers, 1.3k citations indexed

About

Martin Kornacker is a scholar working on Oncology, Pathology and Forensic Medicine and Genetics. According to data from OpenAlex, Martin Kornacker has authored 59 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 19 papers in Pathology and Forensic Medicine and 18 papers in Genetics. Recurrent topics in Martin Kornacker's work include Lymphoma Diagnosis and Treatment (18 papers), Chronic Lymphocytic Leukemia Research (14 papers) and CAR-T cell therapy research (9 papers). Martin Kornacker is often cited by papers focused on Lymphoma Diagnosis and Treatment (18 papers), Chronic Lymphocytic Leukemia Research (14 papers) and CAR-T cell therapy research (9 papers). Martin Kornacker collaborates with scholars based in Germany, United States and Switzerland. Martin Kornacker's co-authors include Anthony D. Ho, Michael R. Verneris, Robert S. Negrin, Manfred Hensel, Volker Diehl, Heribert Bohlen, Christian Scheffold, Volker Mailänder, Juergen Wolf and Philip Kasten and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Martin Kornacker

58 papers receiving 1.2k citations

Peers

Countries citing papers authored by Martin Kornacker

Since Specialization

Citations

This map shows the geographic impact of Martin Kornacker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin Kornacker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin Kornacker more than expected).

Fields of papers citing papers by Martin Kornacker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martin Kornacker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin Kornacker. The network helps show where Martin Kornacker may publish in the future.

Co-authorship network of co-authors of Martin Kornacker

This figure shows the co-authorship network connecting the top 25 collaborators of Martin Kornacker. A scholar is included among the top collaborators of Martin Kornacker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martin Kornacker. Martin Kornacker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	1320MO Early evidence of efficacy in patients (pts) with non-small cell lung cancer (NSCLC) with HER2 exon20 insertion (ex20ins) mutations treated in a phase I study with BAY 2927088 2023 ·Annals of Oncology ·Herbert H. Loong, Gennaro Daniele, (unknown), Ticiana Leal, Kōichi Goto, Yuki Shinno, Kazumi Nishino, Tomohiro Sakamoto, Enriqueta Felip, J.C. Ruffinelli, (unknown), Zhou Wang, Chen Chen, Barbara J. Brennan, (unknown), Martin Kornacker, Paolo Grassi, Xiuning Le, Daniel Shao-Weng Tan, (unknown)	4
2	Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma 2021 ·Blood Advances ·Michael Dickinson, Javier Briones, Alex F. Herrera, Eva González‐Barca, Nilanjan Ghosh, Raúl Córdoba, Sarah C. Rutherford, Eirini Bournazou, Emily Labriola–Tompkins, (unknown), (unknown), Jurriaan Brouwer‐Visser, Katharina Lechner, Barbara J. Brennan, Eveline Nüesch, Mark DeMario, Dominik Rüttinger, Martin Kornacker, Martin Hutchings	29
3	48MO SQZ-PBMC-HPV-101: Preliminary results of a first-in-human, dose-escalation study of a cell-based vaccine in HLA A02+ patients with recurrent, locally advanced, or metastatic HPV16+ solid tumors 2021 ·Annals of Oncology* ·(unknown), Joaquina Baranda, Monica Mita, Wade T. Iams, Michael S. Gordon, Matthew H. Taylor, Neesha C. Dhani, Scott Loughhead, (unknown), Ricardo Zwirtes, Martin Kornacker, O. Rosen, Howard Bernstein, Antonio Jimeno	1
4	A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma 2020 ·British Journal of Cancer ·Geoffrey I. Shapiro, Patricia LoRusso, Afshin Dowlati, T. Khanh, Caron A. Jacobson, Ulka N. Vaishampayan, Amy Weise, Paolo F. Caimi, Joseph P. Eder, Christopher A. French, Emily Labriola–Tompkins, Frédéric Boisserie, William E. Pierceall, Jianguo Zhi, Sharon Passe, Mark DeMario, Martin Kornacker, Philippe Armand	83
5	A Simulation Analysis to Evaluate the Effect of Prospective Biomarker Testing on Progression-Free Survival (PFS) in DLBCL 2017 ·Blood ·Edith Szafer‐Glusman, Juan Liu, Franklin Peale, Thalia A. Farazi, Jill Ray, Carsten Horn, Mikkel Z. Oestergaard, Martin Kornacker, Laurie H. Sehn, Günter Fingerle‐Rowson, Jeffrey M. Venstrom, Michelle Byrtek, Elizabeth A. Punnoose	1
6	BCL2 Expression Identifies a Population with Unmet Medical Need in Previously Untreated (1L) Patients with DLBCL 2017 ·Blood ·Edith Szafer‐Glusman, Franklin Peale, Guiyuan Lei, Anja Mottok, Pedro Farinha, Jill Ray, Thalia A. Farazi, Martin Kornacker, Mikkel Z. Oestergaard, Juan Liu, Randy D. Gascoyne, Elizabeth A. Punnoose	1
7	Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies 2017 ·British Journal of Cancer ·Rastislav Bahleda, Juneko E. Grilley‐Olson, Ramaswamy Govindan, Fabrice Barlési, Laurent Greillier, M. Pérol, Isabelle Ray‐Coquard, Dirk Strumberg, Beate Schultheis, Grace K. Dy, Gérard Zalcman, Glen J. Weiss, Annette O. Walter, Martin Kornacker, Prabhu Rajagopalan, David Henderson, Hendrik Nogai, Matthias Ocker, Jean‐Charles Soria	22
8	Era 223-A Phase 3 Trial of Radium-223 Dichloride (Ra-223) in Combination with Abiraterone Acetate (Aa) and prednisone in the treatment of asymptomatic or mildly symptomatic chemotherapynaïve patients with bone-predominant metastatic Castration Resistant Prostate Cancer (Crpc) 2015 ·Annals of Oncology ·Sergio Bracarda, Giuseppe Procopio, Chris Parker, Bertrand Tombal, (unknown), (unknown), Fang Fang, (unknown), Martin Kornacker, Celestia S. Higano, Matthew Ryan Smith	1
9	Phase IB study of sorafenib in combination with gemcitabine and cisplatin in patients with refractory solid tumors 2011 ·Cancer Chemotherapy and Pharmacology ·Beate Schultheis, (unknown), (unknown), E. Brendel, Chenjing Xia, Martin Kornacker, Dirk Strumberg	10
10	Characteristics of relapse after autologous stem-cell transplantation for follicular lymphoma: a long-term follow-up 2009 ·Annals of Oncology ·Martin Kornacker, (unknown), Christiane Pott, Sascha Dietrich, (unknown), M. Hensel, Maike Nickelsen, Mathias Witzens‐Harig, Michael Kneba, Norbert Schmitz, Anthony D. Ho, Peter Dreger	44
11	Bortezomib in Relapsed Multiple Myeloma – Results of a Non-Interventional Study by Office-Based Haematologists 2009 ·Oncology Research and Treatment ·Wolfgang Knauf, Burkhard Otremba, Friedrich Overkamp, Martin Kornacker	3
12	Cytokine-induced killer cells targeted by the novel bispecific antibody CD19xCD5 (HD37xT5.16) efficiently lyse B-lymphoma cells 2007 ·Cancer Immunology Immunotherapy ·(unknown), Gerhard Moldenhauer, (unknown), Christian Kleist, Anthony D. Ho, Martin Kornacker	34
13	The apoptotic and proliferative fate of cytokine-induced killer cells after redirection to tumor cells with bispecific Ab 2006 ·Cytotherapy ·Martin Kornacker, Michael R. Verneris, (unknown), Tom M. Ganten, Christian Scheffold, Robert S. Negrin	6
14	Combined effect of recombinant CD19xCD16 diabody and thalidomide in a preclinical model of human B cell lymphoma 2004 ·Anti-Cancer Drugs ·Jana Schlenzka, Thomas Moehler, Sergey M. Kipriyanov, Martin Kornacker, Axel Benner, (unknown), Marike Stassar, Holger Schäfer, Melvyn Little, Hartmut Goldschmidt, Björn Cochlovius	18
15	Disease activity and pretreatment, rather than hypogammaglobulinaemia, are major risk factors for infectious complications in patients with chronic lymphocytic leukaemia 2003 ·British Journal of Haematology ·Manfred Hensel, Martin Kornacker, (unknown), Gerlinde Egerer, Anthony D. Ho	52
16	Disease Activity and Pretreatment, but Not Hypogammaglobulinemia, Are Risk Factors for Infectious Complications in Patients with Chronic Lymphocytic Leukemia 2002 ·Blood ·M. Hensel, (unknown), Martin Kornacker, A. D. Ho	1
17	Stem Cell Dose and Tumorbiologic Parameters as Prognostic Markers for Patients with Metastatic Breast Cancer Undergoing High-Dose Chemotherapy with Autologous Blood Stem Cell Support 2002 ·Stem Cells ·Manfred Hensel, Andreas Schneeweiß, Hans‐Peter Sinn, Gerlinde Egerer, Martin Kornacker, Erich Solomayer, Rainer Haas, G. Bastert, Anthony D. Ho	8
18	Hodgkin disease‐derived cell lines expressing ubiquitous mitochondrial creatine kinase show growth inhibition by cyclocreatine treatment independent of apoptosis 2001 ·International Journal of Cancer ·Martin Kornacker, Uwe Schlattner, Theo Wallimann, (unknown), Robert S. Negrin, (unknown), Andrea Staratschek‐Jox, Volker Diehl, Juergen Wolf	21
19	Detection of a Hodgkin/Reed‐Sternberg cell specific immunoglobulin gene rearrangement in the serum DNA of a patient with Hodgkin's disease 1999 ·British Journal of Haematology ·Martin Kornacker, (unknown), Martina Vockerodt, Hans Tesch, Heribert Bohlen, Volker Diehl, Jennifer Moriatis Wolf	16
20	Detection of identical Hodgkin–Reed Sternberg cell specific immunoglobulin gene rearrangements in a patient with Hodgkin’s disease of mixed cellularity subtype at primary diagnosis and in relapse two and a half years later 1998 ·Annals of Oncology ·(unknown), Thomas Zander, Martin Kornacker, Holger Kanzler, Ralf Küppers, Volker Diehl, Juergen Wolf	18

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact